<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">31398464</PMID>
        <DateCompleted>
            <Year>2020</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>05</Month>
            <Day>26</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1879-260X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>1865</Volume>
                    <Issue>11</Issue>
                    <PubDate>
                        <Year>2019</Year>
                        <Month>11</Month>
                        <Day>01</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Biochimica et biophysica acta. Molecular basis of disease</Title>
                <ISOAbbreviation>Biochim Biophys Acta Mol Basis Dis</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of peripheral serotonin synthesis by LP533401 and disturbances in calciotropic hormones attenuated excessive osteoblastogenesis with simultaneous improvement of bone mineral status in 5/6 nephrectomized rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>165528</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0925-4439(19)30245-5</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbadis.2019.08.004</ELocationID>
            <Abstract>
                <AbstractText>Chronic kidney disease (CKD) is a pathological condition associated with renal osteodystrophy for which there are limited treatment options. Gut-derived serotonin (GDS) is one of the key signaling factors controlling the osteoblast proliferation. Previously, we shown that inhibition of GDS synthesis by LP533401 improved bone mineral status of rats with 5/6 nephrectomy-induced CKD model. Here, we investigated whether the use of LP533401 can modify GDS-dependent molecular pathway involved in osteoblast formation and bone mineralization in CKD rats. The 8-weeks of pharmacological manipulation after a complete CKD development reduced GDS and lead to the advantage of endogenous vitamin D [25(OH)D] over serotonin and parathyroid hormone (PTH) in rats treated with LP533401. The imbalance between GDS - 25(OH)D - PTH resulted in the intensified expression of cAMP- responsive element-binding protein (Creb), whereas the expression of myelocytomatosis oncogene (c-Myc) was simultaneously reduced. This lead to disruption of Foxo1- activating transcription factor 4 (Atf4) complex, and decrease in the expression of the major osteogenic markers. The weakening of excessive osteoblastogenesis was associated with better bone mineral status in all rats with CKD, and especially in LP533401-treated animals. In conclusion, the inhibition of GDS synthesis resulted in the mitigation of osteoblastogenesis observed in CKD, which translated into improvement of bone mineral status. This study provides key mechanistic insights into how modification of GDS-dependent molecular pathway affects bone mineral status in CKD and lays the groundwork for translating the role of functional serotonin signaling in the origin of impaired bone mineral status in patients with CKD.</AbstractText>
                <CopyrightInformation>Copyright Â© 2019 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pawlak</LastName>
                    <ForeName>Dariusz</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C Str, 15-222 Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Domaniewski</LastName>
                    <ForeName>Tomasz</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C Str, 15-222 Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sieklucka</LastName>
                    <ForeName>Beata</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacodynamics, Medical University of Bialystok, Mickiewicza 2C Str, 15-222 Bialystok, Poland; Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C Str, 15-222 Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jakuc</LastName>
                    <ForeName>Magdalena</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C Str, 15-222 Bialystok, Poland.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pawlak</LastName>
                    <ForeName>Krystyna</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C Str, 15-222 Bialystok, Poland. Electronic address: krystynapawlak@poczta.onet.pl.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Biochim Biophys Acta Mol Basis Dis</MedlineTA>
            <NlmUniqueID>101731730</NlmUniqueID>
            <ISSNLinking>0925-4439</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C548240">LP533401</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010281">Parathyroid Hormone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018490">Serotonin Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>333DO1RDJY</RegistryNumber>
                <NameOfSubstance UI="D012701">Serotonin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002113" MajorTopicYN="N">Calcification, Physiologic</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010006" MajorTopicYN="N">Osteoblasts</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010012" MajorTopicYN="N">Osteogenesis</DescriptorName>
                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010281" MajorTopicYN="N">Parathyroid Hormone</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName>
                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018490" MajorTopicYN="N">Serotonin Agents</DescriptorName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Bone mineral status</Keyword>
            <Keyword MajorTopicYN="Y">LP533401</Keyword>
            <Keyword MajorTopicYN="Y">Osteoblast proliferation/differentiation</Keyword>
            <Keyword MajorTopicYN="Y">Rat CKD model</Keyword>
            <Keyword MajorTopicYN="Y">Serotonin</Keyword>
            <Keyword MajorTopicYN="Y">Vitamin D</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>26</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2019</Year>
                <Month>07</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2019</Year>
                <Month>08</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>5</Month>
                <Day>27</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>8</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31398464</ArticleId>
            <ArticleId IdType="pii">S0925-4439(19)30245-5</ArticleId>
            <ArticleId IdType="doi">10.1016/j.bbadis.2019.08.004</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>